Tesamorelin
Community reports on tesamorelin — the GHRH analogue used for visceral fat reduction and GH stimulation. Anonymous accounts of protocols, body composition outcomes, and side effects.
2 anonymous reports
We're collecting more reports on this topic.
Submit yourscommunity guides:
Community Q&A
- What is tesamorelin and what does the community use it for?
- Tesamorelin is a GHRH (growth hormone-releasing hormone) analogue with FDA approval for HIV-associated lipodystrophy — specifically visceral fat accumulation. Community accounts split between its approved use and general visceral fat reduction goals. The most common community framing: a targeted tool for stubborn abdominal fat that doesn't respond to diet and exercise, particularly visceral fat rather than subcutaneous. Accounts frequently distinguish tesamorelin from general GH secretagogues by citing its specific visceral fat mechanism and stronger clinical evidence base.
- How effective is tesamorelin for visceral fat reduction?
- Community accounts for visceral fat reduction are among the most specific in the peptide space — users frequently reference baseline measurements, waist circumference changes, and DEXA scan comparisons. The consistent theme: meaningful visceral fat reduction over 3–6 months, with the best-documented accounts describing 15–25% reductions in visceral fat area. Accounts that combine tesamorelin with a caloric deficit consistently describe better outcomes than either alone. The compound is described as selective for visceral fat — accounts note subcutaneous fat responds less strongly, making it distinct from GLP-1s.
- How does tesamorelin compare to sermorelin and CJC-1295?
- Community comparison accounts consistently describe tesamorelin as producing a stronger GH response with more targeted visceral fat effects than sermorelin. CJC-1295 + ipamorelin accounts frame that stack as better for overall body composition and sleep quality; tesamorelin accounts frame it as the better choice when visceral fat reduction is the primary goal. Cost appears in nearly every comparison — tesamorelin is more expensive than sermorelin, and this limits its use to those with a specific therapeutic objective. Accounts that have used all three describe a hierarchy: sermorelin for general wellness, CJC + ipa for body composition, tesamorelin for visceral fat.
- What side effects does tesamorelin cause?
- Community reports on tesamorelin side effects align closely with the GH secretagogue class: water retention in the first weeks (most common), transient joint discomfort at higher doses, and occasional injection site reactions. Glucose effects appear in some accounts — a subset of users report elevated fasting glucose and insulin resistance with extended use, consistent with GH's known metabolic effects. Accounts from users with pre-existing metabolic concerns describe closer monitoring. The side effect burden is generally described as comparable to CJC-1295 rather than markedly different.